SOLVAY PHARMACEUTICALS SA: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
What changed
SOLVAY PHARMACEUTICALS SA
NACE 70.100, Activities of head offices
financial year 2025 compared with 2024filed annual accounts (NBB)
Net result for the year
€904,977
2024 · €2.2m-€1.3m
Equity
€133,309
2024 · €228,333-€95,023
Cash
-
not filed
Balance sheet total
€28.1m
2024 · €32.8m-€4.8m
Largest movements
Assets
- Current investments -€4.6m
down €4.6m (-14.1%), from €32.7m to €28.1m
Equity and liabilities
- Provisions -€3.5m
down €3.5m (-11.6%), from €29.9m to €26.5m
- Other debts -€1.2m
down €1.2m (-54.5%), from €2.2m to €1.0m
Income statement
- Financial income -€4.6m
down €4.6m (-46.0%), from €10.1m to €5.5m
of which Financial income: -€4.6m
- Financial charges -€3.1m
down €3.1m (-40.7%), from €7.6m to €4.5m
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Result 2024
€2.2m
Other operating charges
-€858
Other operating items
-€4,041
Financial income
-€4.6m
Financial charges
+€3.1m
Taxes
+€197,175
Result 2025
€904,977
raises the resultlowers the resultnot broken down further in the accounts
Derived cash bridge
Cash or the result is not a separate line in both sets of accounts; the cash flow cannot be derived from them.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €32,838,012 | €28,072,632 | -€4.8m | -14.5% |
| Current assets | 29/58 | €32,838,012 | €28,072,632 | -€4.8m | -14.5% |
| Amounts receivable within one year | 40/41 | €168,059 | €442 | -€167,617 | -99.7% |
| Trade receivables | 40 | €138,443 | - | -€138,443 | |
| Other amounts receivable | 41 | €29,617 | €442 | -€29,174 | -98.5% |
| Current investments | 50/53 | €32,669,953 | €28,072,190 | -€4.6m | -14.1% |
| Other investments | 51/53 | €32,669,953 | €28,072,190 | -€4.6m | -14.1% |
| Total equity and liabilities | 10/49 | €32,838,012 | €28,072,632 | -€4.8m | -14.5% |
| Equity | 10/15 | €228,333 | €133,309 | -€95,023 | -41.6% |
| Contributions | 10/11 | €100,000 | €100,000 | = | 0.0% |
| Capital | 10 | €100,000 | €100,000 | = | 0.0% |
| Issued capital | 100 | €100,000 | €100,000 | = | 0.0% |
| Reserves | 13 | €10,000 | €10,000 | = | 0.0% |
| Non-distributable reserves | 130/1 | €10,000 | €10,000 | = | 0.0% |
| Legal reserve | 130 | €10,000 | €10,000 | = | 0.0% |
| Profit (loss) carried forward | 14 | €118,333 | €23,309 | -€95,023 | -80.3% |
| Provisions and deferred taxes | 16 | €29,922,561 | €26,452,339 | -€3.5m | -11.6% |
| Provisions for liabilities and charges | 160/5 | €29,922,561 | €26,452,339 | -€3.5m | -11.6% |
| Other liabilities and charges | 164/5 | €29,922,561 | €26,452,339 | -€3.5m | -11.6% |
| Amounts payable | 17/49 | €2,687,119 | €1,486,984 | -€1.2m | -44.7% |
| Amounts payable within one year | 42/48 | €2,687,119 | €1,486,984 | -€1.2m | -44.7% |
| Trade debts | 44 | €331,159 | €330,410 | -€750 | -0.2% |
| Suppliers | 440/4 | €331,159 | €330,410 | -€750 | -0.2% |
| Taxes, remuneration and social security | 45 | €155,959 | €156,573 | +€615 | +0.4% |
| Taxes | 450/3 | €155,959 | €156,573 | +€615 | +0.4% |
| Other amounts payable | 47/48 | €2,200,001 | €1,000,001 | -€1.2m | -54.5% |
| Operating charges | 60/66A | €19,672 | €24,571 | +€4,899 | +24.9% |
| Services and other goods | 61 | €11,094 | €15,134 | +€4,041 | +36.4% |
| Other operating charges | 640/8 | €8,578 | €9,436 | +€858 | +10.0% |
| Operating profit (loss) | 9901 | -€19,672 | -€24,571 | -€4,899 | -24.9% |
| Financial income | 75/76B | €10,113,690 | €5,464,230 | -€4.6m | -46.0% |
| Recurring financial income | 75 | €10,113,690 | €5,463,788 | -€4.6m | -46.0% |
| Income from current assets | 751 | €2,305,485 | €1,292,794 | -€1.0m | -43.9% |
| Other financial income | 752/9 | €7,808,205 | €4,170,995 | -€3.6m | -46.6% |
| Non-recurring financial income | 76B | - | €442 | +€442 | |
| Financial charges | 65/66B | €7,646,791 | €4,533,899 | -€3.1m | -40.7% |
| Recurring financial charges | 65 | €7,646,791 | €4,533,899 | -€3.1m | -40.7% |
| Debt charges | 650 | €614 | €31,908 | +€31,295 | +5,101% |
| Other financial charges | 652/9 | €7,646,177 | €4,501,991 | -€3.1m | -41.1% |
| Profit (loss) for the period before taxes | 9903 | €2,447,227 | €905,760 | -€1.5m | -63.0% |
| Income taxes | 67/77 | €197,959 | €784 | -€197,175 | -99.6% |
| Taxes | 670/3 | €197,959 | €784 | -€197,175 | -99.6% |
| Profit (loss) for the period | 9904 | €2,249,269 | €904,977 | -€1.3m | -59.8% |
| Profit (loss) for the period to be appropriated | 9905 | €2,249,269 | €904,977 | -€1.3m | -59.8% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 29 October 2026 via checked.be.